CTLA-4 Ig as an effective treatment in a patient with type I diabetes mellitus and seropositive rheumatoid arthritis

Anna Laura Fedele, Stefano Alivernini, Elisa Gremese, Gianfranco Ferraccioli

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

We describe a patient suffering from seropositive rheumatoid arthritis (RA) and type I diabetes mellitus (T1DM), who achieved a good EULAR response together with an improvement of the glycemic profile under treatment with CTLA-4 Ig. A close association is known to exist between T1DM and RA, and CTLA-4 exon 1 polymorphism has been associated to RA with coexisting autoimmune endocrinopathies. The possible common genetic background and the potential role of CTLA-4 Ig in the early phases of T1DM, could be considered in the therapeutic interventions in RA patients with type 1 diabetes.
Original languageEnglish
Pages (from-to)315-317
Number of pages3
JournalClinical and Experimental Rheumatology
Volume34
Publication statusPublished - 2016

Keywords

  • diabetes
  • rheumatoid arthritis

Fingerprint

Dive into the research topics of 'CTLA-4 Ig as an effective treatment in a patient with type I diabetes mellitus and seropositive rheumatoid arthritis'. Together they form a unique fingerprint.

Cite this